Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 901–1,000 of 1,003
Antagonism of thromboxane receptors by diclofenac and lumiracoxib
Selg, E., Buccellati, C., Andersson, M., Rovati, G. E., Ezinga, M., Sala, A., Larsson, A., Ambrosio, E., Låstbom, L., Capra, V., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707518 · Cited by 33
“In fact, with some delay, the adverse cardiovascular effects of coxibs emerged most clearly from several long term studies with primary endpoints other than cardiovascular safety, where an increased number of serious adverse cardiovascular events associated with the use of rofecoxib (Bresalier et al., 2005), celecoxib…”
BackgroundWu, D., Mennerich, D., Arndt, K., Sugiyama, K., Ozaki, N., Schwarz, K., Wei, J., Wu, H., Bishopric, N. H., & Doods, H. N. (2009) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2009.06.006 · Cited by 34
Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis
Ohlssen, D., Price, K. L., Amy Xia, H., Hong, H., Kerman, J., Fu, H., Quartey, G., Heilmann, C. R., Ma, H., & Carlin, B. P. (2014) · Pharmaceutical Statistics · doi:10.1002/pst.1592 · Cited by 34
“Concerns about the cardiovascular safety of NSAIDs arose since the withdrawal of rofecoxib [57], a selective COX-2 inhibitor, from the market in 2004 after the results of a randomized placebo-controlled trial showed an increased risk of cardiovascular events associated with the drug [58].”
BackgroundCastellsagué, J., Holick, C. N., Hoffman, C., Gimeno, V., Stang, M., & Perez‐Gutthann, S. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.12.1397 · Cited by 33
Jick, H., Kaye, J. A., Russmann, S., & Jick, S. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.10.1379 · Cited by 33
Venerito, M., Wex, T., & Malfertheiner, P. (2010) · Pharmaceuticals · doi:10.3390/ph3072225 · Cited by 33
Secretome‐based proteomics reveals sulindac‐modulated proteins released from colon cancer cells
Ji, H. L., Greening, D. W., Kapp, E. A., Moritz, R. L., & Simpson, R. J. (2009) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800077 · Cited by 33
“(Because of potential cardiovascular events, the COX-2-specific inhibitors celecoxib [7] and rofecoxib [19] cannot be routinely recommended for this indication.”
BackgroundCOX-2 inhibitors and cardiovascular risk: Inferences based on biology and clinical studies
Marwali, M., & Mehta, J. L. (2006) · Thrombosis and Haemostasis · doi:10.1160/th06-07-0385 · Cited by 38
“Two of these studies were designed to look at the potential chemoprevention effect of COX-2 inhibitor in colorectal adenoma patients, the APC and APPROVe trials (52, 53).”
BackgroundEtoricoxib for arthritis and pain management.
Brooks, P., & Kubler, P. A. (2006) · PubMed Central · Cited by 33
A Perspective on Characterizing Benefits and Risks Derived from Clinical Trials: Can We Do More?
O’Neill, R. T. (2008) · Drug Information Journal · doi:10.1177/009286150804200305 · Cited by 33
Hermann, M., & Ruschitzka, F. T. (2007) · Annals of Medicine · doi:10.1080/07853890601073445 · Cited by 33
“2005 (45) 2586 with a history of colorectal adenomas rofecoxib 25 mg QD versus placebo increased RR for thrombotic event for rofecoxib no NSAID arm; 3.”
BackgroundUnmet Needs in Non-steroidal Anti-inflammatory Drug-induced Upper Gastrointestinal Diseases
Scheiman, J. M. (2006) · Drugs · doi:10.2165/00003495-200666001-00004 · Cited by 33
“cardiovascular events emerged from a number of trials.([12,29,30]) Valdecoxib has similar pharmacological properties to rofecoxib, and was associated”
BackgroundThe use of COX-2 inhibitors for acute dental pain
Huber, M. A., & Terézhalmy, G. T. (2006) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2006.0220 · Cited by 35
Sager, P. T., Heilbraun, J., Turner, J. R., Gintant, G. A., Geiger, M. J., Kowey, P. R., Mansoor, G. A., Mendzelevski, B., Michelson, E. L., Stockbridge, N., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.01.002 · Cited by 38
Characterization of a new mPGES-1 inhibitor in rat models of inflammation
Leclerc, P., Pawelzik, S., Idborg, H., Spahiu, L., Larsson, C., Stenberg, P., Korotkova, M., & Jakobsson, P. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.03.005 · Cited by 32
Ungprasert, P., Srivali, N., & Kittanamongkolchai, W. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.02.05 · Cited by 32
“The adverse effect of non-steroidal anti-inflammatory drugs (NSAIDs), one of the most commonly use medications in patients with AS, on the cardiovascular system is also well-recognized (37-39).”
BackgroundAmlodipine and celecoxib for treatment of hypertension and osteoarthritis pain
Angeli, F., Trapasso, M., Signorotti, S., Verdecchia, P., & Reboldi, G. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1540299 · Cited by 37
“damage, atherosclerotic plaques, and laminar shear forces selectively up-regulate the expression of COX-2 by endothelial cells in an attempt to maintain homoeostasis [57].”
BackgroundNSAIDs-dependent adaption of the mitochondria-proteasome system in immortalized human cardiomyocytes
Brandolini, L., Antonosante, A., Giorgio, C., Bagnasco, M., d’Angelo, M., Castelli, V., Benedetti, E., Cimini, A., & Allegretti, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-75394-x · Cited by 32
Drug-Associated Gastropathy: Diagnostic Criteria
Bordin, D. S., Livzan, M. A., Gaus, O. V., Mozgovoi, S. I., & Lanas, Á. (2023) · Diagnostics · doi:10.3390/diagnostics13132220 · Cited by 47
Tesei, A., Zoli, W., Fabbri, F., Leonetti, C., Rosetti, M., Bolla, M., Amadori, D., & Silvestrini, R. (2008) · Nitric Oxide · doi:10.1016/j.niox.2008.04.007 · Cited by 34
Herndon, C. M., Hutchison, R. W., Berdine, H. J., Stacy, Z. A., Chen, J. T., Farnsworth, D. D., Dang, D. K., & Fermo, J. D. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.6.788 · Cited by 35
Cyclooxygenase products and atherosclerosis
Linton, M. F., & Fazio, S. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.05.006 · Cited by 39
“Increased cardiovascular events observed in the APPROVe trial[16] led to the removal of the selective COX-2 inhibitor rofecoxib from the market.”
BackgroundLaharie, D., Droz‐Perroteau, C., Bénichou, J., Amouretti, M., Blin, P., Bégaud, B., Guiard, E., Dutoit, S., Lamarque, S., Moride, Y., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03588.x · Cited by 32
Renard, J.-F., Arslan, D., Garbacki, N., Pirotte, B., & de Leval, X. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900702b · Cited by 34
van Adelsberg, J., Gann, P. H., Ko, A. T., Damber, J. ‐., Logothetis, C. J., Marberger, M., Schmitz‐Dräger, B. J., Tubaro, A., Harms, C. J., & Roehrborn, C. G. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x219526 · Cited by 32
Hao, H., Hu, S. S., Wan, Q., Xu, C., Chen, H., Zhu, L., Xu, Z., Meng, J., BREYER, R. M., Li, N., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310713 · Cited by 32
González‐Barnadas, A., Camps‐Font, O., Martín‐Fatás, P., Figueiredo, R., Gay‐Escoda, C., & Valmaseda‐Castellón, E. (2019) · Clinical Oral Investigations · doi:10.1007/s00784-019-02910-3 · Cited by 32
“Conversely, more cardiovascular adverse events have been reported with selective COX-2 inhibitors, especially with rofecoxib [3, 4].”
BackgroundAssessing intraepithelial neoplasia and drug safety in cancer-preventive drug development
Kelloff, G. J., & Sigman, C. C. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2154 · Cited by 37
Nelson, W. G. (2007) · Current Opinion in Urology · doi:10.1097/mou.0b013e3280eb110f · Cited by 41
Prieto, A., Barrio, M. D., Martín, E., Fernandez-Bohorquez, M. J., de Castro, F. J., Ruiz, F. J., Herrero, T., Tornero, P., & Rubio, M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.12.616 · Cited by 32
MR Monitoring of Cyclooxygenase-2 Inhibition of Angiogenesis in a Human Breast Cancer Model in Rats
Fournier, L. S., Novikov, V., Lucidi, V., Fu, Y., Miller, T., Floyd, E., Shames, D. M., & Brasch, R. C. (2007) · Radiology · doi:10.1148/radiol.2431050658 · Cited by 35
Cancer chemoprevention: lessons learned and future directions
Brenner, D. E., & Gescher, A. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602765 · Cited by 32
“While many of these trials have been disrupted following recognition of the cardiovascular toxicity of selective cyclooxygenase-2 inhibitors (Bresalier et al, 2005; Solomon et al, 2005), nevertheless, useful data will emerge from these studies, which will ultimately define the chemopreventive…”
BackgroundInfluentialCardiorenal Safety of OTC Analgesics
White, W. B., Kloner, R. A., Angiolillo, D. J., & Davidson, M. H. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417751070 · Cited by 31
Chemoprevention of bladder cancer
Golijanin, D. J., Kakiashvili, D., Madeb, R. R., Messing, E. M., & Lerner, S. P. (2006) · World Journal of Urology · doi:10.1007/s00345-006-0123-x · Cited by 31
“signiWcant elevation in cardiovascular (CV) events [277].”
Ungprasert, P., Srivali, N., & Kittanamongkolchai, W. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.09.012 · Cited by 35
“[6] Bresalier RS, Sandler RS, Quan H, et al.”
BackgroundRao, C. V., Steele, V. E., Swamy, M. V., Patlolla, J. M. R., Guruswamy, S., & Kopelovich, L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1377 · Cited by 32
Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro
McFadden, D. W., Riggs, D. R., Jackson, B., & Cunningham, C. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.4.1019 · Cited by 31
Auman, J. T., Church, R. D., Lee, S., Watson, M. A., Fleshman, J. W., & McLeod, H. L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.010 · Cited by 31
“How do the results from this study inform on the usefulness of celecoxib as an option for colorectal cancer chemotherapy? This is an important issue, since the prolonged use of several selective COX-2 inhibitors, including celecoxib, has been found to increase the risk of cardiovascular side effects.(26,27) However, t…”
Cyclooxygenase‐2 inhibitors and coronary occlusion – exploring dose–response relationships
McGettigan, P., Han, P., & Henry, D. A. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02660.x · Cited by 31
Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Waksman, J. C., Brody, A., & Phillips, S. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1h341 · Cited by 31
Gargiulo, G., Capodanno, D., Longo, G., Capranzano, P., & Tamburino, C. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.964687 · Cited by 31
“Unfortunately, the withdrawal of rofecoxib (Vioxx) was due to increased risk of serious CV events in both the Vioxx Gastrointestinal Outcomes Research trial comparing rofecoxib and naproxen in rheumatoid arthritis and the Adenomatous Polyp Prevention on Vioxx placebo-controlled trial of colorectal adenoma chemoprevent…”
BackgroundAzad, R., Vanaja, G. R., Vyakaranam, P., Rachamallu, A., Reddy, G. V., Anilkumar, K., Arunasree, K. M., Dhyani, A., Prasad, N. K., Sharma, S., et al. (2017) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2017.03.006 · Cited by 37
“The selective COX-2 inhibitors (COXIBs), though devoid of gastric side effects, have been linked with cardiovascular toxicity [20,21].”
BackgroundLarsson, K., Steinmetz, J. L., Bergqvist, F., Arefin, S., Spahiu, L., Wannberg, J., Pawelzik, S., Morgenstern, R., Stenberg, P., Kublickiene, K. R., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14827 · Cited by 33
Sasaki, Y., Nakatani, Y., & Hara, S. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.06.006 · Cited by 31
RNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer
Strillacci, A., Griffoni, C., Valerii, M. C., Lazzarini, G., Tomasi, V., & Spisni, E. (2010) · BioMed Research International · doi:10.1155/2010/828045 · Cited by 32
“Thus, these recent strategies disclose new challenging perspectives for the development of clinically compatible siRNA or miRNA capable of selectively inhibiting COX-2 enzyme.”
Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors
Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., & O’Donnell, V. B. (2006) · Blood · doi:10.1182/blood-2006-02-005330 · Cited by 34
Peroxisome Proliferator‐Activated Receptors and Progression of Colorectal Cancer
Wang, D., & DuBois, R. N. (2008) · PPAR Research · doi:10.1155/2008/931074 · Cited by 31
“[2] R.”
Onset of acute myocardial infarction after use of non‐steroidal anti‐inflammatory drugs
Hammad, T. A., Graham, D. J., Staffa, J. A., Kornegay, C. J., & Pan, G. J. D. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1560 · Cited by 34
Skarke, C., REUS, M., SCHMIDT, R., Grundei, I., Schuss, P., Geißlinger, G., & Lötsch, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.08.021 · Cited by 31
“The positive results regarding PTGS2 pharmacogenetcs and the effects of rofecoxib(24) gave rise to the hope that ocal selective COX-2 inhibition might be based in the uture on PTGS2-personalized prescription of this class of rugs,(26) which have recently been stigmatized because of heir cardiovascular risk.(4,6) Becau…”
BackgroundSelective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients
Vogt, L., de Zeeuw, D., Woittiez, A.-J. J., & Navis, G. J. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn644 · Cited by 34
Relative Thromboembolic Risks Associated with COX-2 Inhibitors
Jones, S. C. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e654 · Cited by 35
Gaziano, J. M., & Gibson, C. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.020 · Cited by 30
Howe, L. R., Subbaramaiah, K., Kent, C. V., Zhou, X. K., Chang, S., Hla, T., Jakobsson, P., Hudis, C. A., & Dannenberg, A. J. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.04.002 · Cited by 30
Pathobiology and Chemoprevention of Bladder Cancer
Tanaka, T., Miyazawa, K., Tsukamoto, T., Kuno, T., & Suzuki, K. A. O. (2011) · Journal of Oncology · doi:10.1155/2011/528353 · Cited by 35
“It should be remembered that long-term exposure to COX-2 inhibitors has the potential to be harmful and has been associated with a well-publicized small, but significant, elevation in cardiovascular (CV) events [245].”
BackgroundFlamiatos, J. F., Beer, T. M., Graff, J. N., Eilers, K. M., Tian, W., Sekhon, H. S., & Garzotto, M. G. (2016) · British Journal of Urology · doi:10.1111/bju.13612 · Cited by 32
Ma, T., Song, X., Ma, Y., Hu, H., Bai, H., Li, Y., & Gao, L. (2021) · Medicine · doi:10.1097/md.0000000000024488 · Cited by 37
Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment
Larsson, K., & Jakobsson, P. (2015) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2015.06.002 · Cited by 30
Cardiovascular effects of cyclooxygenase-2 inhibitors
Brophy, J. M. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mog.0b013e3282f026a7 · Cited by 30
Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs
Krum, H., Swergold, G. D., Gammaitoni, A. R., Peloso, P. M. J., Smugar, S. S., Curtis, S., Brater, D. C., Wang, H., Kaur, A., Laine, L., et al. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00283.x · Cited by 30
“008) [5].”
Evaluation of Anti-nociceptive and Anti-inflammatory Activities of Novel Chalcone Derivatives.
Razmi, A., Zarghi, A., Arfaee, S., Naderi, N., & Faizi, M. (2013) · PubMed Central · Cited by 32
Chakraborty, R., Pydi, S. P., Gleim, S., Bhullar, R. P., Hwa, J., Dakshinamurti, S., & Chelikani, P. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00725-12 · Cited by 30
“, Vioxx) due to increased numbers of cardiovascular events (5) and cardiovascular concerns with nonsteroidal anti-inflammatory drugs (NSAIDs) (e.”
BackgroundCardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs
Gore, M. O., & McGuire, D. K. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0038-4 · Cited by 30
Dawson, S., Michael, M., Biagi, J., Foo, K. F., Jefford, M., Ngan, S. Y., Leong, T., Hui, A., Milner, A., Thomas, R. J. S., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9016-5 · Cited by 30
Barthélémy, O., Limbourg, T., Collet, J., Beygui, F., Silvain, J., Bellemain-Appaix, A., Cayla, G., Chastre, T., Baumgärtner, I., Röther, J., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.06.015 · Cited by 33
“Traditional NSAIDs also appear to carry deleterious CV effects, although this could vary from drug to drug [12–20].”
BackgroundNavarrete, C. M., Fiebich, B. L., de Vinuesa, A. G., Hess, S., de Oliveira, A. C. P., Candelario‐Jalil, E., Caballero, F. J., Calzado, M. A., & Muñóz, E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05966.x · Cited by 36
What is the harm-benefit ratio of Cox-2 inhibitors?
van Staa, T. P., Smeeth, L. L., Persson, I., Parkinson, J., & Leufkens, H. G. M. (2008) · International Journal of Epidemiology · doi:10.1093/ije/dym296 · Cited by 30
Constitutive Cyclooxygenase-2 Is Involved in Central Nociceptive Processes in Humans
Martin, F., Fletcher, D., CHAUVIN, M., & Bouhassira, D. (2007) · Anesthesiology · doi:10.1097/01.anes.0000265162.39932.33 · Cited by 30
Unraveling the Role of Drug-Lipid Interactions in NSAIDs-Induced Cardiotoxicity
Pereira‐Leite, C., Figueiredo, M., Burdach, K., Nunes, C., & Reis, S. (2020) · Membranes · doi:10.3390/membranes11010024 · Cited by 30
“The evidence that cyclooxygenase-2 selective inhibitors were related to the occurrence of thrombotic events [10] raised questions about the CV safety of the entire class of NSAIDs.”
BackgroundSciulli, M. G., Capone, M. L., Tacconelli, S., & Patrignani, P. (2005) · PubMed · Cited by 30
Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD)
Geusens, P. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902926071 · Cited by 33
“However, in studies developed to observe whether the use of COX-2 inhibitors protected against the occurrence of colonic polyps, it has become clear that rofecoxib, as compared with placebo, doubles the risk of thrombotic events, mainly MI and ischemic CV events [23,24].”
BackgroundNSAID enteropathy: could probiotics prevent it?
Montalto, M., Gallo, A., Gasbarrini, A., & Landolfi, R. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0648-2 · Cited by 31
Cyclooxygenase-2 Inhibition and Coagulation
Steffel, J., scher, T. F. L., Ruschitzka, F. T., & Tanner, F. C. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200605001-00004 · Cited by 32
“Recently, a trial designed to prevent recurrent colonic polyps with rofecoxib revealed an increase in cardiovascular events, which led to the withdrawal of rofecoxib from the market.(56) In a similar trial, celecoxib use was associated with a dose-related increase in the composite endpoint of death from cardiovascular…”
BackgroundDahlberg, L., Holme, I., Høye, K., & Ringertz, B. (2009) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740802419065 · Cited by 30
“Concern remains over the safety of long-term use of COX-2 selective NSAIDs following reports of a significantly increased risk of serious cardiovascular events with rofecoxib in the Vioxx Gastrointestinal Outcomes Research (VIGOR) and Adenomatous Polyp Prevention on Vioxx (APPROVe) trials (25, 26).”
BackgroundA Pilot Surrogate Endpoint Biomarker Study of Celecoxib in Oral Premalignant Lesions
Wirth, L. J., Krane, J. F., Li, Y., Othus, M. K. D., Moran, A. E., Dorfman, D. M., Norris, C. M., Goguen, L. A., Posner, M. R., Haddad, R. I., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-07-0003 · Cited by 30
Vallböhmer, D., DeMeester, S. R., Oh, D. S., Banki, F., Kuramochi, H., Shimizu, D., Hagen, J. A., Danenberg, K. D., Danenberg, P. V., Chandrasoma, P. T., et al. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00601.x · Cited by 31
Thromboembolism in Cancer Patients: Pathogenesis and Treatment
Adess, M. E., Eisner, R., Nand, S., Godwin, J. E., Messmore, H. L., & Wehrmacher, W. H. (2006) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029606291432 · Cited by 30
Munir, M. A., Enany, N., & Zhang, J. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2006.10.011 · Cited by 35
Perioperative Pain Control: A Strategy for Management
Cohen, M. J. M., & Schecter, W. P. (2005) · Surgical Clinics of North America · doi:10.1016/j.suc.2005.09.009 · Cited by 34
“In a myelinated axon, transmembrane sodium channels are widely spaced at the nodes of Ranvier, allowing electric potential to ‘‘jump’’ from node to node, thereby increasing the velocity of impulse conduction.”
BackgroundMarkle, B. J., & Goldstein, J. L. (2007) · Evidence-Based Gastroenterology · doi:10.1097/ebg.0b013e31805c9d0f · Cited by 30
Beware of on-treatment safety analyses
Yang, F., Wittes, J., & Pitt, B. (2019) · Clinical Trials · doi:10.1177/1740774518812774 · Cited by 29
“The report of the original analysis only counted cardiovascular events that occurred within 14 days of cessation of study medication.(12) Further follow-up that counted later events increased the estimated relative risk of rofecoxib to placebo.”
BackgroundOverdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation
Rawson, N. S. B. (2007) · JAMA · doi:10.1001/jama.297.6.646 · Cited by 29
MacDonald, T. M., Mackenzie, I. S., Wei, L., Hawkey, C. J., & Ford, I. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002295 · Cited by 30
“an excess of cardiovascular thrombotic events in the group treated with rofecoxib.(4) The Prevention of Sporadic Colorectal Adenomas with Celecoxib (APC) Trial randomised patients with previous colorectal adenomas to celecoxib 400 mg twice daily, celecoxib 200 mg twice daily or placebo and reported a dose-related incr…”
BackgroundFlaxseed orbitides, linusorbs, inhibit LPS-induced THP-1 macrophage inflammation
Zou, X., Shim, Y. Y., Cho, J. Y., Jeong, D., Yang, J. P., Deng, Z., & Reaney, M. J. T. (2020) · RSC Advances · doi:10.1039/c9ra09058d · Cited by 29
Combining repurposed drugs to treat colorectal cancer
Duarte, D., & Vale, N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.012 · Cited by 32
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_8 · Cited by 33
“[1, 6] In The Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial, rofecoxib use was associated with an unacceptable increase in cardiovascular events.”
BackgroundGanswindt, U., Budach, W., Jendrossek, V., Becker, G., BAMBERG, M., & Belka, C. (2006) · Radiation Oncology · doi:10.1186/1748-717x-1-9 · Cited by 30
“Although initially announced to be pain medications with an low and optimal toxicity profile, severe concerns regarding the safety of the coxibes as drug family came up when an increased rate of non-fatal cardiac events was observed in patients treated with rofecoxib for rheumatic disorders over longer periods of time…”
Galliard-Grigioni, K. S., & Reinhart, W. H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.02.042 · Cited by 29
Lamon, B. D., Upmacis, R. K., Deeb, R. S., Koyuncu, H., & Hajjar, D. P. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00144.2010 · Cited by 29
Martelli, A., Testai, L., Anzini, M., Cappelli, A., Capua, A. D., Biava, M., Poce, G., Consalvi, S., Giordani, A., Caselli, G., et al. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.09.008 · Cited by 29
Is etoricoxib effective in preventing heterotopic ossification after primary total hip arthroplasty?
Brunnekreef, J. J., Hoogervorst, P., Ploegmakers, M. J. M., Rijnen, W. H. C., & Schreurs, B. W. (2013) · International Orthopaedics · doi:10.1007/s00264-013-1781-0 · Cited by 29
Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins
Bisoendial, R. J., Stroes, E. S. G., Kastelein, J. J. P., & Tak, P. P. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.277 · Cited by 29
Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries
de Chantemèle, E. J. B., Vessières, E., Guihot, A., Toutain, B., Loufrani, L., & Henrion, D. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp411 · Cited by 29
Lanas, Á., Benito, P., Alonso, J. J., Hernández‐Cruz, B., Barón‐Esquivias, G., Pérez‐Aísa, Á., Calvet, X., García-Llorente, J. F., Gobbo, M., & González‐Juanatey, J. R. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.11.014 · Cited by 32
Laslett, L. L., Quinn, S. J., Darian‐Smith, E., Kwok, M., Fedorova, T., Körner, H., Steels, E., MARCH, L. M., & Jones, G. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.07.019 · Cited by 29
Zhang, Y., Hoda, M. N., Zheng, X., Li, W., Luo, P., Maddipati, K. R., Seki, T., Ergul, A., & Wang, M.-H. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00422.2013 · Cited by 29
“These results are in agreement with clinical data showing long-term use of rofecoxib is associated with a risk of stroke (5, 36).”
ResultClarke, S. J., Yip, S., Brown, C. S. B., Hazel, G. A. V., Ransom, D. T., Goldstein, D., Jeffrey, G. M., Tebbutt, N. C., Buck, M., Lowenthal, R. M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.024 · Cited by 29
Guía sobre el manejo de la angina estable. Versión resumida
Estable, G. D. T. D. L. S. E. D. C. S. E. M. D. L. A. (2006) · Revista Española de Cardiología · doi:10.1157/13092800 · Cited by 38
The problem with NSAIDs: What data to believe?
McKellar, G., Madhok, R., & Singh, G. (2007) · Current Pain and Headache Reports · doi:10.1007/s11916-007-0228-y · Cited by 33
NSAID Single-Drug–Induced Reactions
Woessner, K. M., & Castells, M. (2013) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.12.002 · Cited by 29
Acetaminophen use and change in blood pressure in a hypertensive population
Dawson, J., Fulton, R., McInnes, G. T., Morton, R., Morrison, D., Padmanabhan, S., Hewitt, J., Meredith, P., Muir, S., Dominiczak, A. F., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328360f6f8 · Cited by 27
“There are several mechanisms through which acetaminophen use may cause an increase in BP. Recent data suggest that acetaminophen acts through an indirect effect on the COX-2 enzyme [5,13] and perhaps on a central splice variant of this enzyme, COX-3 [6].”
BackgroundInfluential
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.